Table 1 Patient demographic and baseline characteristics-full-analysis set (FAS)
Variables | N = 31 |
|---|---|
Age in years, median (range) | 54.0(36.0–77.0) |
Sex | |
Female | 30(96.8) |
Male | 1(3.2) |
Countries | |
China | 28(90.3) |
US | 3(9.7) |
Races | |
Asian | 28(90.3) |
Black | 1(3.2) |
White | 2(6.5) |
Postmenopausal or menopausal status | |
Pre-menopausal | 8(25.8) |
Perimenopausal | 4(12.9) |
Postmenopausal | 18(58.1) |
Not reported (male) | 1(3.2) |
ECOG performance-status score* | |
0 | 1(3.2) |
1 | 30(96.8) |
PgR-positive† | |
Yes | 24(77.4) |
No | 7(22.6) |
Histopathology/cytology | |
Ductal | 30(96.8) |
Micropapillary | 1(3.2) |
Sites of metastases | |
Lymph nodes | 20(64.5) |
Bone | 20(64.5) |
Lung | 18(58.1) |
Liver | 15(48.4) |
Brain | 1(3.2) |
Breast | 4(2.9) |
Other | 10(32.3) |
Visceral metastasis | |
Yes | 26(83.9) |
No | 5(16.1) |
Previous systemic therapy | |
One line | 22(71.0) |
Two lines | 9(29.0) |
Number of prior endocrine therapy lines | |
None | 2(6.5) |
One line | 25(80.6) |
Two lines | 4(12.9) |
Chemotherapy | |
Neoadjuvant or adjuvant chemotherapy | 14(45.2) |
For advanced breast cancer | 9(29.0) |
Prior CDK4/6 therapies‡ | |
Yes | 20(64.5) |
No | 11(35.5) |
Not Reported | 0(0) |
Gene mutational status | |
PIK3CA/AKT1/PTEN alterations | 18(58.1) |
ESR1 mutation | 9(29.0) |
